Clint, a former federal prosecutor, is a member of the firm’s nationally ranked Government Investigations and White Collar Litigation Department. An experienced litigator, Clint defends companies and individuals in high-stakes white collar litigation, government investigations, and regulatory proceedings. Clint also conducts internal investigations, develops compliance programs, and advises on regulatory issues involving the Federal Food, Drug and Cosmetic Act (FDCA) and related healthcare laws.
Clint joins McGuireWoods after serving as an assistant director of the United States Department of Justice (DOJ) Consumer Protection Branch, where he conducted and supervised complex healthcare and economic crime investigations and prosecutions. While at DOJ, Clint developed expertise in handling corporate criminal matters in the healthcare and life sciences sectors, including as to pharmaceuticals and medical devices, clinical trial fraud, healthcare fraud, kickbacks, nursing home fraud, drug diversion, pharmacy compounding, and foreign drug importation. Clint also handled a wide range of economic crime investigations and litigation, including matters involving grant and loan fraud, elder fraud, smuggling and customs violations, money laundering, identity fraud, and transnational fraud schemes targeting U.S. victims. Clint’s work included extensive collaboration with the DOJ Civil Fraud Section on qui tam (whistleblower) False Claims Act investigations.
Before his tenure at the DOJ, Clint served in various capacities with the FDA’s Office of the Chief Counsel, where he supported the agency’s Health Care Fraud and Abuse Control (HCFAC) program and worked closely with the Center for Drug Evaluation and Research (CDER), the Center for Devices and Radiological Health (CDRH), and the Office of Criminal Investigations (OCI). Clint advised on legal issues related to drug and device clinical research, application integrity, manufacturing (including cGMP and QSR requirements), advertising and promotion, and safety reporting, as well as on food, dietary supplement, and tobacco product regulation. Clint also handled criminal jury trials and appeals while serving as a Special Assistant U.S. Attorney in multiple jurisdictions.
Prior to his government service, Clint worked in private practice defending clients in a variety of white collar and complex civil litigation matters, including investigations and litigation involving healthcare fraud, bank fraud, securities fraud, public corruption, and pharmaceutical products liability.
Clint’s unique background enables him to provide insightful and practical advice to clients facing regulatory challenges. His proactive approach helps clients address potential issues before they escalate, ensuring compliance and minimizing risk. In situations where the government pursues enforcement action, Clint leverages his extensive prosecutorial experience to aggressively defend his clients’ rights in litigation.
-
University of Pennsylvania Carey Law SchoolJD
magna cum laude, Order of the Coif
2000 - University of California, BerkeleyBA1996
- Presenter, "What the DOJ and FDA are Looking for in Compliance Programs," Compliance Conversations by Healthicity, January 30, 2025
- Moderator, "FDA and DOJ Clinical Trials Oversight – The Impact of Industry Modernization and Best Practices," Food and Drug Law Institute (FDLI), Enforcement, Litigation, and Compliance Conference, December 10, 2024
- Presenter, "Research Fraud and Misconduct," Health Care Compliance Association (HCCA), Healthcare Enforcement Compliance Conference, November 20, 2024
- Panelist, "Life Sciences Regulatory Essentials: What Investors Should Know," 17th Annual Healthcare Finance & Growth Conference, September 25 - 26, 2024
- Presenter, "Enforcement Issues in Drug and Device Research," Health Care Compliance Association (HCCA), Research Compliance Conference, 2023
- Presenter, "Enforcement in Research," HCCA, Healthcare Enforcement Compliance Conference, 2023
- Presenter, "Clinical Trials: Deconstructing Challenges and Providing Practical Insights," Food and Drug Law Institute, 2022
- Hon. Alfred T. Goodwin, U.S. Court of Appeals for the Ninth Circuit, 2001-2002
- District of Columbia
- Author, Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies, McGuireWoods Legal Alert, January 29, 2025
- Author, Dairy Industry Alerted to New USDA Order Requiring National Raw Milk Testing, McGuireWoods Legal Alert, December 10, 2024
- Author, Recent FDA Guidance Signals Future Growth for Decentralized Clinical Trials, McGuireWoods Legal Alert, October 24, 2024
- Author, Key Takeaways From the 2024 Healthcare Finance and Growth Conference, McGuireWoods Legal Alert, October 15, 2024